Roche comes out against allowing takeover of drug manufacturer Catalent
Adds comment from Novo Holdings in paragraph 13
Roche CEO: not good to limit competition in this space
Roche says not itself, but others affected by Catalent deal
Swiss drugmaker joins US peer Lilly in voicing opposition
Eli Lilly and advocacy groups also voice concerns over the deal
Novo Nordisk and Catalent defend the acquisition, citing ample competition
By Ludwig Burger
FRANKFURT, Oct 23 (Reuters) -The CEO of pharmaceuticals giant Roche ROG.S said authorities should block the takeover of contract drug manufacturer Catalent CTLT.N by Novo Nordisk's controlling shareholder, as it could hit competition in the booming weight-loss drug industry.
Though it stressed on Wednesday it was not itself affected, Roche is among the first drugmakers to voice opposition to the transaction with potentially wide-ranging repercussions for weight-loss drugs based on the gut hormone GLP-1.
"Limiting the competition in this space is not a good idea," Roche's CEO Thomas Schinecker said in a media call. "From an industry perspective, it would be a wrong decision by authorities."
"It could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available," he told journalists, speaking after the release of quarterly sales on Wednesday.
The company said it would not comment further on any interactions with competition authorities.
"In general, if companies start buying up CMOs (contract manufacturing organisations), that will limit the amount of competition that there can be," Schinecker added in a later analyst call.
Last week, an alliance of U.S. consumer, patient and workers advocacy groups petitioned the U.S. Federal Trade Commission to block Novo Holdings, which controls Novo Nordisk NOVOb.CO, from acquiring Catalent, saying the deal threatened competition in weight loss drugs and gene therapies.
Executives at Eli Lilly LLY.N, Novo's main rival in the obesity and diabetes drug market, have repeatedly voiced concerns over the transaction, which will also see Novo Nordisk take direct ownership of three Catalent sites where injection pens are filled in Italy, Belgium and the United States.
The advocacy groups said at the time that the deal could constrain competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche and AstraZeneca AZN.L, which are reportedly developing their own obesity drugs, some of which are based on difficult-to-make peptides.
Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS could also be affected, the advocacy groups said.
A Novo Nordisk spokesperson, commenting on the Roche CEO's remarks, said: "If the acquisition is approved, Novo Nordisk will purchase three manufacturing sites from Novo Holdings. Catalent will still operate close to 50 sites independently and separate from Novo Nordisk."
The Novo Nordisk spokesperson said that a "large number" of other contract drugmakers compete with Catalent and said that, if the acquisition is approved, pharma and biotech companies "will continue to have access to ample choice for contract manufacturing, including Catalent." The spokesperson reiterated the company's expectation that the transaction will close towards the end of this year.
Novo Holdings said Catalent would continue to operate independently as a leading contract drug manufacturer.
Catalent said: "We are confident that the transaction is pro-competitive, and we are unaware of any competitive GLP-1 products being manufactured for commercial sale at the three sites that Novo Nordisk is planning to acquire."
It added it would continue to work closely with European and U.S. regulators and that it still expected the transaction to close towards the end of 2024.
Novo would not be the first pharma major to run contract manufacturing operations serving rivals, as Pfizer PFE.N and Boehringer Ingelheim, for example, also own such divisions.
The head of Roche's pharmaceutical division, Teresa Graham, underscored on Wednesday that Roche itself was not impacted: "We are quite confident in the capacity we have. We have reserved capacity with other CMOs."
When asked last week to comment on scrutiny of the Catalent deal, Roche said it would use both in-house and external manufacturing for future commercial production of its obesity drugs.
Additional reporting by Maggie Fick in London, Editing by Rachel More, Tomasz Janowski, Mark Potter and David Evans
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
